The Blood–Brain Barrier in Health and Disease by Sweilem B. Al Rihani, Yazan S. Batarseh, Amal Kaddoumi

Get full text

Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition by Malavika Deodhar, Sweilem B. Al Rihani, Lucy Darakjian, Jacques Turgeon, Veronique Michaud

Get full text

ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System by Veronique Michaud, Malavika Deodhar, Meghan Arwood, Sweilem B Al Rihani, Pamela Dow, Jacques Turgeon

Get full text

Disease-Induced Modulation of Drug Transporters at the Blood–Brain Barrier Level by Sweilem B. Al Rihani, Lucy I. Darakjian, Malavika Deodhar, Pamela Dow, Jacques Turgeon, Veronique Michaud

Get full text

Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy by Sweilem B. Al Rihani, Matt K. Smith, Ravil Bikmetov, Malavika Deodhar, Pamela Dow, Jacques Turgeon, Veronique Michaud

Get full text

Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice by Malavika Deodhar, Sweilem B Al Rihani, Meghan J. Arwood, Lucy Darakjian, Pamela Dow, Jacques Turgeon, Veronique Michaud

Get full text

Adverse drug event risk assessment by the virtual addition of COVID‐19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation study... by Matt K. Smith, Ravil Bikmetov, Sweilem B. Al Rihani, Malavika Deodhar, Matthew Hafermann, Pamela Dow, Jacques Turgeon, Veronique Michaud

Get full text